Enterprise Value
779.6M
Cash
546.5M
Avg Qtr Burn
-39.87M
Short % of Float
12.44%
Insider Ownership
12.42%
Institutional Own.
-
Qtr Updated
03/31/24
Drug Pipeline
Powered by
![](/BPIQ_Pill.png)
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Birtamimab Details Rare diseases, Amyloid light chain amyloidosis | Phase 3 Data readout | |
NNC6019 (PRX004) Details Rare diseases, Transthyretin amyloidosis | Phase 2/3 Data readout | |
Prasinezumab (alpha-synuclein) Details Parkinson's disease, Neurodegenerative disease | Phase 2 Data readout | |
BMS-986446 / PRX005 (anti-tau) Details Alzheimer's disease | Phase 2 Initiation | |
PRX012 (amyloid beta) Details Alzheimer's disease | Phase 1 Update | |
PRX019 Details Neurodegenerative disease | Phase 1 Initiation | |
PRX123 Details Alzheimer's disease | Phase 1 Initiation |